ArticleJugan geon-gang gwa jilbyeong2025
Characteristics of Notified Carbapenem-resistant
Article in Jugan geon-gang gwa jilbyeong, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Dissemination ofEmerging microbes & infections · 2026Article
- Comparison of Antimicrobial Susceptibility Patterns of Bacterial Isolates from Blood, Urine, and Lower Respiratory Tract Specimens Between Elderly Patients in Long-Term Care Hospitals and Community-Acquired Infections: A Retrospective Study.Antibiotics (Basel, Switzerland) · 2026Article
- Characteristics of Carbapenem-ResistantPublic health weekly report · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Carbapenem-resistant Methods: CRE cases reported to the Korea Disease Control and Prevention Agency in 2024, were analyzed, focusing on demographic characteristics, types of healthcare facilities, and pathogen profiles. Results: A total of 42,347 CRE cases were reported from 1,610 healthcare facilities, including 33,169 CP-CRE cases from 1,313 facilities. The proportion of CP-CRE among CRE cases increased from 61.9% in 2020 to 78.3% in 2024. General hospitals accounted for 19,006 cases (44.9%), advanced general hospitals for 10,905 (25.8%), and long-term care hospitals (LTCHs) for 8,940 (21.1%). The reports from LTCHs increased from 8.2% in 2020 to 21.1% in 2024. Regionally, 26,624 cases (62.9%) were reported in the Capital area. Among reported isolates, Conclusions: Since the introduction of mandatory surveillance in 2017, the number of CRE cases and reporting healthcare facilities have steadily increased. The upward trend in reports from LTCHs is likely to reflect multiple factors, including population aging as well as patient- and facility-related characteristics. Considering the genotype-specific trends and regional variations, tailored strategies for the early detection of CP-CRE outbreaks are warranted. Sustained collaboration between the public and private sectors is crucial for effective CRE control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.